Zymeworks (ZYME) News Today $12.51 +0.16 (+1.30%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$12.51 0.00 (0.00%) As of 03/27/2025 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Zymeworks Inc.: Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual MeetingMarch 26 at 9:18 AM | finanznachrichten.deInsiders Make Huge Purchases of These 4 Biotech StocksMarch 26 at 8:40 AM | 247wallst.comZymeworks to Engage Investors at Upcoming ConferencesMarch 26 at 6:34 AM | tipranks.comZymeworks Announces Participation in Upcoming Investor ConferencesMarch 26 at 6:00 AM | globenewswire.comZymeworks Inc. (NYSE:ZYME) Director Acquires $296,772.12 in StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc purchased 22,689 shares of Zymeworks stock in a transaction that occurred on Monday, March 24th. The shares were purchased at an average price of $13.08 per share, for a total transaction of $296,772.12. Following the transaction, the director now directly owns 17,157,802 shares in the company, valued at $224,424,050.16. This represents a 0.13 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.March 25 at 8:08 PM | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Purchases $396,601.74 in StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc acquired 31,033 shares of the stock in a transaction dated Friday, March 21st. The stock was acquired at an average price of $12.78 per share, with a total value of $396,601.74. Following the completion of the acquisition, the director now owns 17,135,113 shares in the company, valued at approximately $218,986,744.14. The trade was a 0.18 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.March 25 at 8:08 PM | marketbeat.comZymeworks Inc. (ZYME): Among Stocks Receiving the Most Insider Love in MarchMarch 25 at 6:15 PM | msn.comZymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual MeetingMarch 25 at 4:30 PM | globenewswire.comZymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Buys 22,689 SharesMarch 25 at 4:22 AM | insidertrades.comHillsdale Investment Management Inc. Purchases Shares of 230,025 Zymeworks Inc. (NYSE:ZYME)Hillsdale Investment Management Inc. acquired a new stake in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 230,025 shares of the company's stock, valued at approximately $3,368,000. HillsdMarch 24, 2025 | marketbeat.comBank of New York Mellon Corp Has $1.77 Million Stock Holdings in Zymeworks Inc. (NYSE:ZYME)Bank of New York Mellon Corp cut its stake in Zymeworks Inc. (NYSE:ZYME - Free Report) by 51.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 120,683 shares of the company's stock after selling 129,30March 23, 2025 | marketbeat.comInsiders Are Spending Big: 15 Stocks Leading in MarchMarch 22, 2025 | insidermonkey.comQ1 Earnings Forecast for Zymeworks Issued By Leerink PartnrsZymeworks Inc. (NYSE:ZYME - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Zymeworks in a research note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst A. Berens anticipates that the company will post earningMarch 21, 2025 | marketbeat.comInsider Buying: Zymeworks Inc. (NYSE:ZYME) Director Purchases 56,277 Shares of StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc bought 56,277 shares of the stock in a transaction on Monday, March 17th. The stock was bought at an average price of $12.23 per share, for a total transaction of $688,267.71. Following the completion of the purchase, the director now directly owns 16,858,418 shares in the company, valued at approximately $206,178,452.14. The trade was a 0.33 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.March 20, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 58,306 SharesZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc purchased 58,306 shares of the company's stock in a transaction that occurred on Wednesday, March 19th. The stock was bought at an average price of $12.64 per share, with a total value of $736,987.84. Following the purchase, the director now owns 17,030,604 shares of the company's stock, valued at approximately $215,266,834.56. The trade was a 0.34 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.March 20, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 56,277 SharesMarch 20, 2025 | insidertrades.comPlatinum Investment Management Ltd. Has $4.49 Million Holdings in Zymeworks Inc. (NYSE:ZYME)Platinum Investment Management Ltd. trimmed its holdings in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 6.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 306,460 shares of the company's stock after selling 21,062 sharesMarch 20, 2025 | marketbeat.comTejara Capital Ltd Invests $564,000 in Zymeworks Inc. (NYSE:ZYME)Tejara Capital Ltd purchased a new position in Zymeworks Inc. (NYSE:ZYME - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 38,537 shares of the company's stock, valued at approximately $564,000. Tejara CapMarch 19, 2025 | marketbeat.comPicton Mahoney Asset Management Reduces Holdings in Zymeworks Inc. (NYSE:ZYME)Picton Mahoney Asset Management lowered its position in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 15.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 206,569 shares of the company's stock after selling 38March 17, 2025 | marketbeat.comLifeSci Capital Initiates a Buy Rating on Zymeworks (ZYME)March 15, 2025 | markets.businessinsider.comHuge Insider Buying: Victoria's Secret, Carl Icahn, and MoreMarch 15, 2025 | 247wallst.comMonaco Asset Management SAM Reduces Position in Zymeworks Inc. (NYSE:ZYME)Monaco Asset Management SAM cut its position in Zymeworks Inc. (NYSE:ZYME - Free Report) by 95.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,000 shares of the company's stock after selling 285,000March 15, 2025 | marketbeat.comEcor1 Capital, Llc Buys 320,690 Shares of Zymeworks Inc. (NYSE:ZYME) StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc bought 320,690 shares of the business's stock in a transaction on Tuesday, March 11th. The shares were acquired at an average price of $11.49 per share, for a total transaction of $3,684,728.10. Following the completion of the transaction, the director now owns 16,040,851 shares in the company, valued at approximately $184,309,377.99. This trade represents a 2.04 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.March 14, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 468,356 SharesZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc bought 468,356 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was purchased at an average price of $12.48 per share, with a total value of $5,845,082.88. Following the purchase, the director now directly owns 16,802,141 shares of the company's stock, valued at $209,690,719.68. The trade was a 2.87 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.March 14, 2025 | marketbeat.comInsider Buying: Zymeworks Inc. (NYSE:ZYME) Director Acquires 320,690 Shares of StockMarch 14, 2025 | insidertrades.comQ1 Earnings Forecast for Zymeworks Issued By Lifesci CapitalZymeworks Inc. (NYSE:ZYME - Free Report) - Equities research analysts at Lifesci Capital issued their Q1 2025 earnings per share estimates for shares of Zymeworks in a research report issued on Tuesday, March 11th. Lifesci Capital analyst C. Zhu anticipates that the company will post earnings perMarch 14, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Shares Sold by Jupiter Asset Management Ltd.Jupiter Asset Management Ltd. cut its stake in Zymeworks Inc. (NYSE:ZYME - Free Report) by 13.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 369,499 shares of the company's stock after selling 57,445March 14, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesZymeworks Inc. (NYSE:ZYME - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight research firms that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a stronMarch 13, 2025 | marketbeat.comZymeworks (ZYME) Shares Surge Amid Positive Analyst ForecastsMarch 12, 2025 | markets.businessinsider.comZymeworks (ZYME) Soars 5.4%: Is Further Upside Left in the Stock?March 12, 2025 | msn.comZymeworks (ZYME) Gets a Hold from Wells FargoMarch 12, 2025 | markets.businessinsider.comZymeworks (NYSE:ZYME) Coverage Initiated by Analysts at Lifesci CapitalLifesci Capital initiated coverage on Zymeworks in a report on Tuesday. They set an "outperform" rating and a $30.00 target price on the stock.March 12, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for Zymeworks Q1 Earnings?Zymeworks Inc. (NYSE:ZYME - Free Report) - HC Wainwright lifted their Q1 2025 earnings per share estimates for shares of Zymeworks in a report issued on Monday, March 10th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.43) for the quarter, upMarch 12, 2025 | marketbeat.comAnalysts Just Shipped A Captivating Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) EstimatesMarch 11, 2025 | finance.yahoo.comZymeworks initiated with an Outperform at LifeSci CapitalMarch 11, 2025 | markets.businessinsider.comLifeSci Capital Initiates Coverage of Zymeworks (ZYME) with Outperform RecommendationMarch 11, 2025 | msn.comZymeworks (ZYME) Receives a Buy from LifeSci CapitalMarch 11, 2025 | markets.businessinsider.comZymeworks (NYSE:ZYME) Price Target Raised to $13.00HC Wainwright raised their price objective on shares of Zymeworks from $12.00 to $13.00 and gave the stock a "neutral" rating in a research note on Monday.March 11, 2025 | marketbeat.comZymeworks price target raised to $13 from $12 at H.C. WainwrightMarch 10, 2025 | markets.businessinsider.comCitigroup Forecasts Strong Price Appreciation for Zymeworks (NYSE:ZYME) StockCitigroup lifted their price objective on Zymeworks from $18.00 to $19.00 and gave the stock a "buy" rating in a research report on Friday.March 8, 2025 | marketbeat.comZymeworks Inc. Initiates First-in-Human Studies for ZW191 and ZW171; Accelerates IND Submission for ZW251 and Receives FDA Approval for Ziihera®March 7, 2025 | nasdaq.comZymeworks (ZYME) Gets a Buy from Evercore ISIMarch 7, 2025 | markets.businessinsider.comZymeworks price target raised to $19 from $18 at CitiMarch 7, 2025 | markets.businessinsider.comZymeworks (NYSE:ZYME) Shares Gap Down - Here's WhyZymeworks (NYSE:ZYME) Shares Gap Down - What's Next?March 7, 2025 | marketbeat.comCancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251March 6, 2025 | benzinga.comZymeworks Inc.: Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 6, 2025 | finanznachrichten.deZymeworks Inc. (NYSE:ZYME) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | msn.comZymeworks Reports 2024 Financial Results and Pipeline ProgressMarch 5, 2025 | tipranks.comZymeworks reports Q 4EPS (31c), consensus (9c)March 5, 2025 | markets.businessinsider.comZymeworks Inc. (ZYME) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | seekingalpha.com Remove Ads Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYME Media Mentions By Week ZYME Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZYME News Sentiment▼1.340.79▲Average Medical News Sentiment ZYME News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZYME Articles This Week▼185▲ZYME Articles Average Week Remove Ads Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AKRO News ALVO News RYTM News MRUS News IMVT News VKTX News PTGX News CRNX News SRRK News BHVN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ZYME) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
